Travere Therapeutics (TVTX) Bank of America Global Healthcare Conference 2026 summary

Company overview and recent milestones

• Focused on rare kidney diseases, with innovative therapies for IgA nephropathy and FSGS, and a phase III program in classical homocystinuria.

• Recently received FDA approval for FILSPARI in FSGS, marking the first approved therapy for this condition.

• FILSPARI is positioned as a foundational therapy, replacing ACE inhibitors/ARBs and complementing steroids for long-term kidney protection.

• Addressable patient populations: over 30,000 for FSGS and 70,000 for IgA nephropathy, both expected to grow with increased awareness and earlier diagnosis.

• Phase III pegtibatinase program targets classical homocystinuria, aiming to reduce homocysteine and improve quality of life.

FILSPARI launch and market dynamics

• Early feedback from physicians and the patient community has been overwhelmingly positive, with high anticipation for the therapy.

• Uptake in FSGS is expected to be faster than in IgA nephropathy due to higher unmet need and established brand equity.

• Steady, linear uptake anticipated, influenced by quarterly patient visits and strong prescriber overlap between FSGS and IgAN.

• Education focuses on dosing differences, indication nuances, and the nephroprotective profile of FILSPARI.

• Early payer feedback is positive, with higher first-pass approval rates for FSGS compared to IgAN, aided by existing formulary inclusion.

Industry trends and competitive landscape

• First-to-market advantage for FILSPARI in FSGS is significant, with a long lead time before potential competitors arrive.

• Additional therapies are seen as complementary and market-expanding rather than direct threats.

• Industry focus is shifting toward earlier diagnosis and intervention, supported by evolving guidelines and increased biopsy rates.

• Proteinuria is now widely accepted as a surrogate endpoint, encouraging earlier treatment and clinical trial participation.

• Combination approaches and more aggressive early intervention are expected to drive further market growth.